Regulations for Approval of Specific Medicinal Products' Manufacturing or Importing as a Special Case Article 4
While the central competence authority reviews the application in accordance with the preceding two articles, shall take the situation, risk and benefit, and amounts calculation methods listed in Paragraph 1 of Article 48-2 of the Act into consideration. When approved, it may be with additional conditions imposed.While the central competence authority make the decision of approval or disapproval may consult with scholars or professionals or convenes an expert review meeting when necessary, and may publicize the scholars and expert opinions or conference related information or medical products’ approval assessment report, but the authority shall keep in confidence any trade secrets.
中文原文 特定藥物專案核准製造及輸入辦法第4條
中央衛生主管機關受理前二條之申請,應審酌本法第四十八條之二第一項各款規定之情事、利益風險及數量計算方式,為准駁之決定;核准時,得為附款。
中央衛生主管機關為前項准駁之決定,必要時得諮詢學者專家或召開專家審查會議,並得公開學者專家意見、會議相關資訊、會議紀錄或藥物核准審查報告摘要。
但對於藥商之營業秘密資料,應予保密。
中央衛生主管機關為前項准駁之決定,必要時得諮詢學者專家或召開專家審查會議,並得公開學者專家意見、會議相關資訊、會議紀錄或藥物核准審查報告摘要。
但對於藥商之營業秘密資料,應予保密。